CAJ | 학술논문

目的探讨X染色体相关凋亡抑制因子(XIAP)在移行细胞癌(TCC)组织中的表达及意义, 方法应用免疫组化S-P法、蛋白质印迹法、RT-PCR法检测43例TCC(肾盂癌6例、输尿管癌2例、膀胱癌35例)以及12例正常移行上皮细胞组织中XIAP蛋白及mRNA表达水平,并采用t检验和方差分析进行统计学比较. 结果 XIAP蛋白及mRNA表达在TCC和正常移行上皮组织(S-P法:22±5和16±2;蛋白质印迹法:1.21±0.15和0.61±0.24;mRNA:1.17+0.30和0.75±0.17)、膀胱癌复发者与初发者(S-P法:24±3和20±3;蛋白质印迹法:1.66±0.28和1.10±0.23;mRNA:1.44±0.27和1.05±0.23)之间比较差异有统计学意义(P<0.05).而在TCC分级、膀胱癌与输尿管和肾盂癌、膀胱癌分期以及膀胱癌单发与多发之间XIAP表达比较差异均无统计学意义(P>0.05), 结论 XIAP在TCC中呈高表达,可能是促进移行上皮恶变的一个重要因素.膀胱癌复发者XIAP表达较初发者明显增高,检测XIAP表达可能成为判断膀胱癌预后、预防膀胱癌复发的新指标.
목적 탐토X염색체상관조망억제인자(XIAP)재이행세포암(TCC)조직중적표체급의의, 방법응용면역조화S-P법、단백질인적법、RT-PCR법검측43례TCC(신우암6례、수뇨관암2례、방광암35례)이급12례정상이행상피세포조직중XIAP단백급mRNA표체수평,병채용t검험화방차분석진행통계학비교. 결과 XIAP단백급mRNA표체재TCC화정상이행상피조직(S-P법:22±5화16±2;단백질인적법:1.21±0.15화0.61±0.24;mRNA:1.17+0.30화0.75±0.17)、방광암복발자여초발자(S-P법:24±3화20±3;단백질인적법:1.66±0.28화1.10±0.23;mRNA:1.44±0.27화1.05±0.23)지간비교차이유통계학의의(P<0.05).이재TCC분급、방광암여수뇨관화신우암、방광암분기이급방광암단발여다발지간XIAP표체비교차이균무통계학의의(P>0.05), 결론 XIAP재TCC중정고표체,가능시촉진이행상피악변적일개중요인소.방광암복발자XIAP표체교초발자명현증고,검측XIAP표체가능성위판단방광암예후、예방방광암복발적신지표.
Objective To study the relationship between X-linked inhibitor of apoptosis protein (XIAP) expression and transitional cell carcinoma(TCC) development. Methods Forty-three TCC tissues and 12 normal transitional epithelial tissues were applied to detect XIAP expression by semi-quantitative RT-PCR, immunohistochemistry and western blot. The data were statistically analyzed by using SPSS11.5 according to the 2 groups (TCC and normal transitional epithelial) as well as the dif-ferent subgroups (tumor stage, grade, single or multiple tumor, primary or recurrence tumor). Results XIAP expression in TCC tissues was higher than in normal transitional epithelial tissues(im-munohistochemistry: 22±5 and 16±2, Western blot:1.21±0. 15 and 0. 61±0.24, mRNA: 1.17± 0. 30 and 0. 75±0. 17, P<0. 05). In the bladder tumors group, XIAP expression in recurrence tumors was higher than in primary tumors(immunohistochemistry: 24±3 and 20±3, Western blot: 1.66±0.28 and 1.10±0. 23, mRNA: 1.44±0. 27 and 1.05±0. 23, P<0. 05). However, there were no significant differences according to the tumor stage and tumor grade as well as tumor multi-plicity or not. Conclusion XIAP expression might serve as a biomarker in TCC diagnosis and recur-rence prediction.